MTAP Deletion Clinical Trials

6 recruitingLast updated: June 17, 2026

There are 6 actively recruiting mtap deletion clinical trials across 34 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Chicago, Illinois, United States, Houston, Texas, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


MTAP Deletion Trials at a Glance

6 actively recruiting trials for mtap deletion are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Chicago, Houston, and Boston. Lead sponsors running mtap deletion studies include Bristol-Myers Squibb, Northwestern University, and PharmaEngine.

Browse mtap deletion trials by phase

Treatments under study

About MTAP Deletion Clinical Trials

Looking for clinical trials for MTAP Deletion? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MTAP Deletion trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MTAP Deletion clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Metastatic Malignant Solid NeoplasmMetastatic Bladder Urothelial CarcinomaMTAP Deletion+1 more
Northwestern University64 enrolled2 locationsNCT06630416
Recruiting
Phase 1

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Advanced Solid Tumors With Homozygous MTAP Deletion
Bristol-Myers Squibb8 enrolled3 locationsNCT06672523
Recruiting
Phase 2Phase 3

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled311 locationsNCT07063745
Recruiting
Phase 1Phase 2

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled18 locationsNCT06922591
Recruiting
Phase 1

A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors With Homozygous MTAP Deletion
Shouyao Holdings (Beijing) Co. LTD122 enrolled1 locationNCT07469982
Recruiting
Phase 1

A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors

Advanced Solid TumorSolid TumorsMTAP Deletion+1 more
PharmaEngine40 enrolled4 locationsNCT06973863